O-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer
Sandler A, Mininberg E, Henderson T, Kim E, Hong W, Mass R, Novotny W, Garcia B, Herbst R, Johnson D. O-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer. Lung Cancer 2003, 41: s36. DOI: 10.1016/s0169-5002(03)91770-3.Peer-Reviewed Original Research